These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 15534909)

  • 1. End-of-treatment virologic response does not predict relapse after lamivudine treatment for chronic hepatitis B.
    Liu CJ; Huang WL; Chen PJ; Lai MY; Kao JH; Chen DS
    World J Gastroenterol; 2004 Dec; 10(24):3574-8. PubMed ID: 15534909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of clinical, biochemical and viral factors associated with early relapse after lamivudine treatment for hepatitis B e antigen-negative chronic hepatitis B patients in Taiwan.
    Huang YH; Wu JC; Chang TT; Sheen IJ; Lee PC; Huo TI; Su CW; Wang YJ; Chang FY; Lee SD
    J Viral Hepat; 2003 Jul; 10(4):277-84. PubMed ID: 12823594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative polymerase chain reaction assay for serum hepatitis B virus DNA as a predictive factor for post-treatment relapse after lamivudine induced hepatitis B e antigen loss or seroconversion.
    Lee HC; Suh DJ; Ryu SH; Kim H; Shin JW; Lim YS; Chung YH; Lee YS
    Gut; 2003 Dec; 52(12):1779-83. PubMed ID: 14633962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Durability of lamivudine-induced HBeAg seroconversion for chronic hepatitis B patients with acute exacerbation.
    Lee CM; Ong GY; Lu SN; Wang JH; Liao CA; Tung HD; Chen TM; Changchien CS
    J Hepatol; 2002 Nov; 37(5):669-74. PubMed ID: 12399235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term follow-up of lamivudine treatment in patients with severe acute exacerbation of hepatitis B e antigen (HBeAg)-positive chronic hepatitis B.
    Wong VW; Wong GL; Tsang SW; Hui AY; Chim AM; Yiu KK; Chan HY; Chan FK; Sung JJ; Chan HL
    Antivir Ther; 2008; 13(4):571-9. PubMed ID: 18672536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A three-month course of lamivudine therapy in HBeAg-positive hepatitis B patients with normal aminotransferase levels.
    Yalçin K; Değertekin H; Kokoğlu OF; Ayaz C
    Turk J Gastroenterol; 2004 Mar; 15(1):14-20. PubMed ID: 15264116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of lamivudine in HBeAg-positive chronic hepatitis B: discordant effect on HBeAg and HBV DNA according to pretreatment ALT level.
    Kurihara T; Imazeki F; Yokosuka O; Fukai K; Kanda T; Kawai S; Saisho H
    World J Gastroenterol; 2005 Jun; 11(22):3346-50. PubMed ID: 15948237
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term additional lamivudine therapy enhances durability of lamivudine-induced HBeAg loss: a prospective study.
    Ryu SH; Chung YH; Choi MH; Kim JA; Shin JW; Jang MK; Park NH; Lee HC; Lee YS; Suh DJ
    J Hepatol; 2003 Oct; 39(4):614-9. PubMed ID: 12971973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon.
    Hartman C; Berkowitz D; Shouval D; Eshach-Adiv O; Hino B; Rimon N; Satinger I; Kra-Oz T; Daudi N; Shamir R
    Pediatr Infect Dis J; 2003 Mar; 22(3):224-9. PubMed ID: 12634582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Extended lamivudine retreatment for chronic hepatitis B: maintenance of viral suppression after discontinuation of therapy.
    Dienstag JL; Schiff ER; Mitchell M; Casey DE; Gitlin N; Lissoos T; Gelb LD; Condreay L; Crowther L; Rubin M; Brown N
    Hepatology; 1999 Oct; 30(4):1082-7. PubMed ID: 10498663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short-term lamivudine therapy in patients with chronic hepatitis B.
    Chien RN; Liaw YF
    Intervirology; 2003; 46(6):362-6. PubMed ID: 14688453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Viral genotype and baseline load predict the response to adefovir treatment in lamivudine-resistant chronic hepatitis B patients.
    Buti M; Elefsiniotis I; Jardi R; Vargas V; Rodriguez-Frias F; Schapper M; Bonovas S; Esteban R
    J Hepatol; 2007 Sep; 47(3):366-72. PubMed ID: 17561304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of antiviral response in HBeAg-positive chronic hepatitis B patients who maintained virologic response for one year after lamivudine discontinuation.
    Kim JH; Lee SJ; Joo MK; Kim CH; Choi JH; Jung YK; Yim HJ; Yeon JE; Park JJ; Kim JS; Bak YT; Byun KS
    Dig Dis Sci; 2009 Jul; 54(7):1572-7. PubMed ID: 18975080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of baseline parameters and on-treatment hepatitis B virus DNA levels to start and continue patients with lamivudine therapy.
    Yuen MF; Fung J; Seto WK; Wong DK; Yuen JC; Lai CL
    Antivir Ther; 2009; 14(5):679-85. PubMed ID: 19704171
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral response is not sustained after cessation of lamivudine treatment in chronic hepatitis B patients: A 10-year follow-up study.
    Kang SH; Kang K; Jong Eun Y; Lee YS; Kim TS; Yoo YJ; Suh SJ; Yoon EL; Jung YK; Kim JH; Seo YS; Yim HJ; Byun KS
    J Med Virol; 2017 May; 89(5):849-856. PubMed ID: 27769101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of baseline viral factors with response to lamivudine therapy in chronic hepatitis B patients with high serum alanine aminotransferase levels.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Chen DS; Kao JH
    Antivir Ther; 2009; 14(2):203-10. PubMed ID: 19430095
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of peginterferon alpha-2a (40KD) in HBeAg-positive chronic hepatitis B patients.
    Caruntu FA; Streinu-Cercel A; Gheorghe LS; Grigorescu M; Sporea I; Stanciu C; Andronescu D; Voinea F; Diculescu M; Oproiu A; Voiosu R
    J Gastrointestin Liver Dis; 2009 Dec; 18(4):425-31. PubMed ID: 20076814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B e antigen seroconversion after lamivudine therapy is not durable in patients with chronic hepatitis B in Korea.
    Song BC; Suh DJ; Lee HC; Chung YH; Lee YS
    Hepatology; 2000 Oct; 32(4 Pt 1):803-6. PubMed ID: 11003626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Factors associated with response to lamivudine: retrospective study of 233 patients with chronic hepatitis B].
    Zhou HJ; Li SG; Wen FY; Yang XY; Wu JL; Tan B; Fu J
    Zhonghua Gan Zang Bing Za Zhi; 2009 Aug; 17(8):564-8. PubMed ID: 19719911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High rates of early HBeAg seroconversion and relapse in Indian patients of chronic hepatitis B treated with Lamivudine: results of an open labeled trial.
    Alexander G; Baba CS; Chetri K; Negi TS; Choudhuri G
    BMC Gastroenterol; 2005 Sep; 5():29. PubMed ID: 16164746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.